News

Summit draws Neutral view on risk/reward setup as Piper initiates biotech cancer names

Summit Therapeutics (SMMT) draws a Neutral rating from Piper Sandler, as the brokerage issues bullish ratings on eight other cancer-focused biotechs. Read more here.

Piper Sandler initiates coverage of oncology companies

Discover Piper Sandler's latest biotech oncology picks, ratings, and price targets. Gain expert insights on CGON, BCAX, DAWN, ...